Ministry of Health

Biomeme Supports Biosecurity Surveillance Program Launched by Ginkgo Bioworks and the Ukraine Ministry of Health

Retrieved on: 
Monday, March 20, 2023
Cloud, Concept, U.S. Army Public Health Center, Partnership, Biosecurity, SARS-CoV-2, Public, Concentric objects, Ginkgo Bioworks, PCR, Infection, Data analysis, Ginkgo, Risk, Commercial, Ministry of Health, Vaccine

PHILADELPHIA, March 20, 2023 /PRNewswire-PRWeb/ -- Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health announced the launch of a pilot program for wastewater-based pathogen monitoring, in partnership with Biomeme. The goal of this program is to provide continuous data on infectious pathogens, such as SARS-CoV-2 and influenza, to minimize the impact of infectious diseases on the people of Ukraine. This program complements Biomeme's expanding range of biosecurity testing solutions, including the identification of biowarfare agents, infectious diseases, industrial hygiene, and environmental health CONOPs.

Key Points: 
  • Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health announced the launch of a pilot program for wastewater-based pathogen monitoring in partnership with Biomeme.
  • PHILADELPHIA, March 20, 2023 /PRNewswire-PRWeb/ -- Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health announced the launch of a pilot program for wastewater-based pathogen monitoring , in partnership with Biomeme.
  • This program complements Biomeme's expanding range of biosecurity testing solutions, including the identification of biowarfare agents, infectious diseases, industrial hygiene, and environmental health CONOPs.
  • Concentric by Ginkgo, Ginkgo Bioworks' biosecurity and public health unit, has partnered with the Ukraine Ministry of Health to design a practical solution for monitoring biological threats found in critical wastewater systems, including sewage systems and natural waterways.

Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award

Retrieved on: 
Friday, March 10, 2023
Acquisition, D&I, DE, Ministry of Health, FY, D, Armourers and Brasiers' Company Prize, Ministry of Health, Labour and Welfare, Empowerment, NPO, Organization, Ministry, Diversity, Female, Patient, Accreditation, Basic category, Ministry of Economy, Trade and Industry, Equity, Knowledge, The Excellence in Diversity Awards, Eisai, Collaborative innovation network, R, Auction, Nursing, Health

TOKYO, Mar 10, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win).

Key Points: 
  • TOKYO, Mar 10, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win).
  • The "J-Win Diversity Award" has been held annually since 2008 with the aim of accelerating the promotion of diversity and inclusion (D&I) in Japanese companies by awarding leading businesses that are promoting D&I.
  • - Plans to introduce a new personnel assessment system from FY 2023, which utilizes a behavioral assessment item "Diversity & Synergy" to further focus on diversity.
  • Eisai aims to realize the spiral of knowledge generated by diversity, regardless of differences in nationality, gender, age, etc., leading to the creation of innovation.

SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome

Retrieved on: 
Monday, March 6, 2023
Yale University, Hannover Medical School, Tel Aviv Sourasky Medical Center, Movement, European Medicines Agency, Ministry of Health (Israel), Ministry, Tic, TEL, TS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Central nervous system, Patient, Learning, Tourette syndrome, Food, Yale Global Tic Severity Scale, Institutional review board, Ethics, FDA, Ministry of Health, Medical device, Safety, Pharmaceutical industry, Health

The Company has already received ethics committee approvals from the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel.

Key Points: 
  • The Company has already received ethics committee approvals from the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel.
  • The Company is currently preparing to submit a request for approval to the Institutional Review Board of Yale University, Connecticut, USA (“Yale’s IRB”).
  • Tics may be associated with a premonitory sensation to perform a specific action, which may lead to “relief” once performed.
  • “With the successful manufacturing of the clinical batches, we are one step closer to initiate this important clinical trial.”

Mexico Needs mpox Vaccine, Says AHF and Vaccine Advocates in The Lancet Letter

Retrieved on: 
Wednesday, March 8, 2023
LGBTQ+, AIDS, Health, Consumer, Infectious Diseases, Pharmaceutical, Science, Bangladesh Technical Education Board, Travel, Public sector, Federal Commission for the Protection against Sanitary Risk, Mpox, CDC, Ministry of Health (Saudi Arabia), Public health emergency of international concern, Infection, Vaccine, European Medicines Agency, MPOX, Ministry, Centers for Disease Control and Prevention, AIDS Healthcare Foundation, Risk, HIV, Disease, STI, AHF, WHO, Director general, Death, Public, NGO, COVID-19, Letter, Policy, Viral disease, Trade Wars, COFEPRIS, World Health Organization, Oregon Higher Education Coordinating Commission, SSA, Ministry of Health, Pharmaceutical industry, Medical device, EU, Lancet

The European Medicines Agency and the US FDA have also authorized the use of the vaccine.

Key Points: 
  • The European Medicines Agency and the US FDA have also authorized the use of the vaccine.
  • Among the authors of this study is the highest decision-maker in public health in Mexico, Dr. Hugo López-Gatell, Undersecretary of Health.
  • The letter was accepted and finally published by the same magazine in its correspondence section titled " MPOX vaccines are needed in Mexico ,” on March 6, 2023.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

National Comprehensive Cancer Network Announces Collaboration with Blood Cancer Experts in Poland

Retrieved on: 
Monday, February 27, 2023
Medicine, Ministry, MD, Policy, Organization, Transfusion medicine, Patient, Ministry of Health, Bone marrow, Republic, Journal of the National Comprehensive Cancer Network, Hematology, AFI, NCCN, MENA, Cancer, Medical device, Health

PLYMOUTH MEETING, Pa., Feb. 27, 2023 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announced a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland (IHIT), and the Alliance For Innovation—Polish-American Foundation (AFI). The three organizations have signed an agreement enabling clinicians to share their established expertise and international experience in order to improve quality of care and outcomes for patients with hematologic malignancies in Poland and around the world.

Key Points: 
  • New international agreement builds on existing work to improve cancer care and outcomes worldwide by adapting and implementing evidence-based guidelines for Poland and beyond.
  • PLYMOUTH MEETING, Pa., Feb. 27, 2023 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® ( NCCN ®)—a not-for-profit alliance of leading United States cancer centers—announced a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland ( IHIT ), and the Alliance For Innovation—Polish-American Foundation ( AFI ).
  • "The Institute of Hematology and Transfusion Medicine in Poland is the leading medical and research hospital in Poland for hematology; it serves as a national clinical and diagnostic reference center.
  • The initial work with Poland launched in 2021 ; to date, the groups have co-developed Polish NCCN Guidelines Adaptations for:

National Comprehensive Cancer Network Announces Collaboration with Blood Cancer Experts in Poland

Retrieved on: 
Monday, February 27, 2023
Medicine, Ministry, MD, Policy, Organization, Transfusion medicine, Patient, Ministry of Health, Bone marrow, Republic, Journal of the National Comprehensive Cancer Network, Hematology, AFI, NCCN, MENA, Cancer, Medical device, Health

PLYMOUTH MEETING, Pa., Feb. 27, 2023 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announced a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland (IHIT), and the Alliance For Innovation—Polish-American Foundation (AFI). The three organizations have signed an agreement enabling clinicians to share their established expertise and international experience in order to improve quality of care and outcomes for patients with hematologic malignancies in Poland and around the world.

Key Points: 
  • New international agreement builds on existing work to improve cancer care and outcomes worldwide by adapting and implementing evidence-based guidelines for Poland and beyond.
  • PLYMOUTH MEETING, Pa., Feb. 27, 2023 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® ( NCCN ®)—a not-for-profit alliance of leading United States cancer centers—announced a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland ( IHIT ), and the Alliance For Innovation—Polish-American Foundation ( AFI ).
  • "The Institute of Hematology and Transfusion Medicine in Poland is the leading medical and research hospital in Poland for hematology; it serves as a national clinical and diagnostic reference center.
  • Together, we can make sure more people with blood cancers receive region-appropriate treatment based on the latest evidence and expert consensus."

Premier Health Reports First Quarter Results

Retrieved on: 
Wednesday, February 22, 2023
Federation, Ministry, Corporation, Ministry of Health (New Zealand), SAP ERP, Ministry of Health, Automation, SAP, Growth, Government, CHCA, Structure of the Canadian federal government, Premier Health Partners, Nursing, Rupture, Health insurance, Health, LIPH

The gross margin for the quarter was 23.5% slightly below our long-term target of 25%, but in-line with expectations for the first quarter.

Key Points: 
  • The gross margin for the quarter was 23.5% slightly below our long-term target of 25%, but in-line with expectations for the first quarter.
  • Ministry of Health regular changes in operational directives in Quebec related to the state of health emergency continued to affect revenues in Q1-2023.
  • Acquisition of Ontario based CHCA in the third quarter of FY2022 continues to contribute positively to earnings.
  • The Ontario agency was acquired in April and contributed to the company’s results for the full first quarter of 2023.

Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Friday, January 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Ministry of Health, Bristol Myers Squibb, TYK2, European Commission, Journal, CHMP, Light, Apremilast, NYSE, Lower respiratory tract infection, Civil service commission, Patient, Face, Committee, Skin, Folliculitis, Food, Ministry, BMY, Committee for Medicinal Products for Human Use, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Academy, FDA, Journal of the American Academy of Dermatology, Ministry of Health, Labour and Welfare, Quality of life, Psoriasis, European, PSO, MD, Pharmaceutical industry, Deucravacitinib, EU

Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.
  • Sotyktu, an oral medication taken once-daily, is a first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
  • The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU).
  • Bristol Myers Squibb thanks the patients and investigators involved in the POETYK PSO clinical trial program.

Body Fluid Collection and Diagnostic Market Report 2022: Surging Demand for Fluid Analysis Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 24, 2023
Health, General Health, DNA, Ministry of Health, Indian Council of Medical Research, Polymerase chain reaction, BD, DSM-IV codes, Fluid mechanics, Laboratory, Government, Blood, Human, Infection, Integration, Congo, NGS, Patient, Diagnosis, PCR, Tissue, Saliva, Proteinuria, Incidence, Region, University of Tokyo, Polymerase, Mindray, University, Ministry, USD, Medical research, Fluorescence, Cerebrospinal fluid, FISH, Democratic republic, Collection, Urine, Growth, Partnership, Chronic kidney disease, In situ hybridization, COVID, Conditional sentence, COVID-19, Hematology, DTC, Medical device, Pharmaceutical industry, Vaccine

The body fluid collection and diagnostic market size is estimated to be USD 30,525.12 million in 2022 and is expected to witness a CAGR of 7.87% during the forecast period 2023-2033.

Key Points: 
  • The body fluid collection and diagnostic market size is estimated to be USD 30,525.12 million in 2022 and is expected to witness a CAGR of 7.87% during the forecast period 2023-2033.
  • It is anticipated that the rising demand for Direct-to-Consumer testing (DTC) will increase demand for body fluid collection and make it simpler for end users to gather samples.
  • A number of players directly sell DTC sample collection kits to consumers and then analyse the samples they collect.
  • Body fluid testing has benefits for disease diagnosis and monitoring, including low cost, low invasiveness, and speedy sample collection and processing.

Patient Simulators Global Market Report 2023: Sector to Reach $4.28 Billion by 2028 at a 15.2% CAGR

Retrieved on: 
Monday, February 20, 2023
Ministry of Health, Organization, Patient safety, Blood, Anatomy, Safety, Patient, Lens, Artificial intelligence, Ministry, Nanotechnology, Approximation error, Student, Gastrointestinal tract, Heart, Growth, Exercise, Mannequin, Observation, COVID-19, Virtual reality, Robotics, Generic drug, Medical device, Nursing, Health

DUBLIN, Feb. 20, 2023 /PRNewswire/ -- The "Patient Simulators Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 20, 2023 /PRNewswire/ -- The "Patient Simulators Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product and End User" report has been added to ResearchAndMarkets.com's offering.
  • The patient simulators market is expected to grow from US$ 1,599.41 million in 2021 to US$ 4,284.03 million by 2028; it is estimated to register a CAGR of 15.2% from 2022 to 2028.
  • The market growth is attributed to the growing use of patient simulators for training purposes and the increasing demand for minimally invasive treatment methods.
  • 7.2 Patient Simulators Market Revenue Share, by Product 2021 & 2028 (%)
    8.2 Global Patient Simulators Market, by End User 2021 & 2028 (%)